Valeant Pharmaceuticals International Inc (VRX)

16.40
0.36 2.24
NYSE : Health Care
Prev Close 16.04
Open 16.28
Day Low/High 16.13 / 16.47
52 Wk Low/High 13.00 / 92.42
Volume 9.43M
Avg Volume 14.88M
Exchange NYSE
Shares Outstanding 347.67M
Market Cap 5.58B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Higher for Eighth Straight Session as Retailers Rise

Dow Higher for Eighth Straight Session as Retailers Rise

The Dow Jones Industrial Average climbs for its eighth straight session in a row on Tuesday as better-than-expected earnings from Walmart lift spirits for the retail earnings season.

Stock Futures Rise After Walmart, Home Depot Top Earnings Estimates

Stock Futures Rise After Walmart, Home Depot Top Earnings Estimates

Stock futures moved higher on Tuesday as positive earnings from retailers including Walmart and Home Depot lifted spirits across the board.

European Benchmarks Fall, But London Bucks Trend on Takeover Activity

European Benchmarks Fall, But London Bucks Trend on Takeover Activity

Kraft Heinz's offer for Unilever boosted the FTSE 100 in London, but markets were in the red elsewhere.

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

Astrazeneca stock rose Friday after the company said that its Lynparza drug fared well in clinical trials of its effectiveness as a breast cancer treatment.

Eli Lilly Is Great Stock to Buy Now

Eli Lilly Is Great Stock to Buy Now

Here's why the pharmaceutical company is a solid addition to your portfolio.

Valeant, Pershing Square to Split Legal Fees on Allergan Lawsuit

Valeant, Pershing Square to Split Legal Fees on Allergan Lawsuit

The two will split litigation fees 50-50.

L'Oreal Stock Drops as Market Digests Body Shop Future

L'Oreal Stock Drops as Market Digests Body Shop Future

L'Oreal stock falls more than 2% on Friday following an after-hours announcement on the future of the Body Shop.

L'Oreal Said to Consider Sale of The Body Shop Ahead of Full-Year Earnings

L'Oreal Said to Consider Sale of The Body Shop Ahead of Full-Year Earnings

L'Oreal is said to be working with Lazard on options for The Body Shop, as it focuses on skincare lines.

TransDigm Shares Rally on Results, But Shortseller Left Stays Bearish

TransDigm Shares Rally on Results, But Shortseller Left Stays Bearish

The aircraft components maker posted earnings of $2.57 a share on revenue of $814 million, beating analysts' forecasts.

Will Mondelez Report its 13th Straight Quarterly Revenue Decline?

Will Mondelez Report its 13th Straight Quarterly Revenue Decline?

The snack company will announce its full-year 2016 results on Tuesday.

Trump Investing: Listen, Don't Overreact

Trump Investing: Listen, Don't Overreact

Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

Dow, S&P 500 Close to a Downside Move

Dow, S&P 500 Close to a Downside Move

Consider shorting UnitedHealth Group at current levels.

Analysts dismiss Citron's sour take on TransDigm

Analysts dismiss Citron's sour take on TransDigm

A report calling the supplier the Valeant of aerospace was greeted with jeers from the sell side. There's reason for concerns about the company regardless.

Short-Seller Andrew Left Says Trump Should Target This Aerospace Stock

Short-Seller Andrew Left Says Trump Should Target This Aerospace Stock

Citron Research says TransDigm could be the Valeant of the Aerospace industry.

Allergan, Schlumberger, IBM: Doug Kass' Views

Allergan, Schlumberger, IBM: Doug Kass' Views

Doug Kass shares his thoughts on animal spirits, and discusses his astonishment at some rising optimism.

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

Valeant's CEO Tries to Pitch Wall Street On the 'New Valeant' Being Very Different

Valeant's CEO Tries to Pitch Wall Street On the 'New Valeant' Being Very Different

CEO Joe Papa tried to distance the company from its past troubles at the annual J.P. Morgan Healthcare Conference.

Valeant Pharmaceuticals CEO Joe Papa Looks to Reassure Investors

Valeant Pharmaceuticals CEO Joe Papa Looks to Reassure Investors

Shares of the specialty pharmaceutical company were slightly higher on Wednesday after its CEO tried to reassure investors that the troubled company is moving in the right direction.

Celebrate One Debacle of a Merger With Another -- ICYMI

Celebrate One Debacle of a Merger With Another -- ICYMI

America Online and Time Warner see the 17-year anniversary of their combination come and go, as both companies are involved in separate merger dramas today.

Closing Bell: Stock Indices Split, Chipotle Surges While Ascena Slumps

Closing Bell: Stock Indices Split, Chipotle Surges While Ascena Slumps

The three major equity indices finished mixed, with the Nasdaq showing the best performance for the day.

Nasdaq Hits Another Record Close While the Dow Flounders

Nasdaq Hits Another Record Close While the Dow Flounders

A scattered day of trading leaves stocks mixed on Tuesday with the Nasdaq enjoying a record close for its third day in a row and the Dow lost ground again.

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks turn mixed on Tuesday, though the Nasdaq remains on track to set to record a close for its third day in a row.

Cramer: How Small Business Can Have a Big Impact on the Market

Cramer: How Small Business Can Have a Big Impact on the Market

Survey says: Maybe business is getting better.

Here's What Valeant Could Still Divest

Here's What Valeant Could Still Divest

Hint: Salix is still up for grabs.

Jim Cramer on L'Oreal's Deal for Valeant's Skin Care Lines

Jim Cramer on L'Oreal's Deal for Valeant's Skin Care Lines

Cramer looks back on his previous criticism of Valeant following L'Oreal deal.